Business
With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Aligos Chief Executive Officer Lawrence Blatt told BioSpace that the different assets in development address different components of the infection.
At the six-year mark, 90.6% of patients in the Perjeta cohort have not had breast cancer return, compared to 87.8% in the placebo arm. This comes to an absolute benefit of 2.8%.
Amgen announced the 240,000-square-foot facility, which is still under construction, will house the company’s Bay Area employees focused on cardiometabolic, inflammation and oncology, research.
Dr. Spychala Brings Patient-Centricity and Rare Disease Clinical Research Expertise to New Role
Locana, Inc., a leading RNA-targeting gene therapy company, announced the appointment of James Burns, Ph.D., as chief executive officer, as a key step in expanding the experienced leadership team and as part of a planned transition of the company’s director and recent CEO, Jeffrey M. Ostrove, Ph.D., to continue service as director..
BioArctic AB will be strengthening its management team in 2020 through two strategic recruitments.
Creoptix AG announced the appointment of Line Stigen Raquet as Chief Executive Officer with effect from beginning of January 2020.
“We still have some work in front of us, but we’re happy where we are,” said Jeff Hawkins, CEO of Truvian Sciences.
The new company, based in Cambridge, Mass., launched with a platform that “digitizes and quantifies cellular behaviors” in order to understand the dynamics that govern those behaviors.
Despite having one of the best-selling insulin products on the market, Sanofi is exiting diabetes and cardiovascular research and development in favor of more lucrative areas, particularly cancer research.